drugset / Trial / NCT05155722

Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors

NCT05155722

Phase 1 Completed 59 enrolled Bio-Thera Solutions
NaSingle-groupOpen-labelTreatment

Summary

A phase I dose escalation and cohort expansion study to evaluate the safety, tolerance and pharmacokinetic of BAT1308 injection in patients with advanced solid tumors

Timeline

Start
2020-09-17
Primary completion
2024-07-09
Completion
2024-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject BAT1308 Monoclonal antibody 100 mg
Subject BAT1308 Monoclonal antibody 300 mg
Subject BAT1308 Monoclonal antibody 600 mg

Indications